Health Care & Life Sciences » Biotechnology | Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,084.00
1,734.00
1,944.00
843.00
-
150
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
32.00
-
Gross Income
-
-
-
-
32.00
-
SG&A Expense
18,988.00
23,997.00
17,904.00
14,860.00
9,459.00
9,669
EBIT
17,974.00
22,437.00
16,170.00
14,150.00
9,491.00
9,548
Unusual Expense
570.00
322.00
51.00
-
-
-
Non Operating Income/Expense
5,511.00
104.00
274.00
339.00
910.00
592
Pretax Income
11,880.00
22,649.00
16,486.00
13,774.00
8,463.00
8,625
Income Tax
1,670.00
3,243.00
2,144.00
1,983.00
993.00
1,337
Consolidated Net Income
10,210.00
19,406.00
14,342.00
11,791.00
7,470.00
7,288
Net Income
10,210.00
19,406.00
14,342.00
11,791.00
7,470.00
7,288
Net Income After Extraordinaries
10,267.00
19,425.00
14,342.00
11,791.00
7,470.00
7,288
Net Income Available to Common
19,478.00
19,587.00
14,543.00
11,991.00
14,846.00
7,489
EPS (Basic)
15.36
10.68
5.40
3.50
1.95
0.62
Basic Shares Outstanding
1,263.20
1,829.60
2,713.10
3,425.00
7,631.20
12,094.10
EPS (Diluted)
15.42
10.71
5.36
3.50
1.95
0.62
Diluted Shares Outstanding
1,263.20
1,829.60
2,713.10
3,425.00
7,631.20
12,094.10
EBITDA
17,904.00
22,263.00
15,960.00
14,017.00
9,459.00
9,519
Non-Operating Interest Income
13.00
6.00
9.00
37.00
118.00
331
Preferred Dividends
9,325.00
200.00
201.00
200.00
7,376.00
201

About Cyclacel Pharmaceuticals

View Profile
Address
200 Connell Drive
Berkeley Heights New Jersey 07922
United States
Employees -
Website http://www.cyclacel.com
Updated 07/08/2019
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.